145 related articles for article (PubMed ID: 35732348)
1. The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer.
Hung JT; Chen IJ; Ueng SH; Huang CS; Chen SC; Chen MY; Lin YC; Lin CY; Campbell MJ; Rugo HS; Yu AL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732348
[TBL] [Abstract][Full Text] [Related]
2. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
Huang CS; Yu AL; Tseng LM; Chow LWC; Hou MF; Hurvitz SA; Schwab RB; L Murray J; Chang HK; Chang HT; Chen SC; Kim SB; Hung JT; Ueng SH; Lee SH; Chen CC; Rugo HS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718986
[TBL] [Abstract][Full Text] [Related]
3. GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Rugo HS; Cortes J; Barrios CH; Cabrera P; Xu B; Huang CS; Kim SB; Melisko M; Nanda R; Pieńkowski T; Rapoport BL; Schwab R
Future Oncol; 2022 Oct; ():. PubMed ID: 36268941
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
5. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
6. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO
Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO
Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967
[TBL] [Abstract][Full Text] [Related]
8. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
9. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.
Wang ZG; Williams LJ; Zhang XF; Zatorski A; Kudryashov V; Ragupathi G; Spassova M; Bornmann W; Slovin SF; Scher HI; Livingston PO; Lloyd KO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2719-24. PubMed ID: 10716997
[TBL] [Abstract][Full Text] [Related]
11. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
[TBL] [Abstract][Full Text] [Related]
13. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
15. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
16. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
Aarntzen EH; de Vries IJ; Göertz JH; Beldhuis-Valkis M; Brouwers HM; van de Rakt MW; van der Molen RG; Punt CJ; Adema GJ; Tacken PJ; Joosten I; Jacobs JF
Cancer Immunol Immunother; 2012 Nov; 61(11):2003-11. PubMed ID: 22527252
[TBL] [Abstract][Full Text] [Related]
17. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
18. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.
Gilewski T; Ragupathi G; Bhuta S; Williams LJ; Musselli C; Zhang XF; Bornmann WG; Spassova M; Bencsath KP; Panageas KS; Chin J; Hudis CA; Norton L; Houghton AN; Livingston PO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3270-5. PubMed ID: 11248068
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.
Slovin SF; Ragupathi G; Adluri S; Ungers G; Terry K; Kim S; Spassova M; Bornmann WG; Fazzari M; Dantis L; Olkiewicz K; Lloyd KO; Livingston PO; Danishefsky SJ; Scher HI
Proc Natl Acad Sci U S A; 1999 May; 96(10):5710-5. PubMed ID: 10318949
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
